Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a ω-(arylsulfonyl)alkylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ω-(arylsulfonyl)alkylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of C, or a pharmaceutically acceptable salt thereof:
2. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, ointments, or patches.
3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethyl ether, caprylic/capric triglyceride, octisalate, silicone fluid, squalene, and sunflower oil.
4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethyl ether.
5. The pharmaceutical composition according to claim 4 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.
6. The pharmaceutical composition according to claim 1 , wherein the compound has at least 90% (w/w) purity, and the composition is in an oral form of tablets or capsules.
7. A method of treating inflammation, comprising the steps of:
identifying a subject suffering from inflammation, and
administering to the subject the pharmaceutical composition of claim 1 , in an amount effective to treat inflammation.
8. The method according to claim 7 , wherein said method reduces or alleviates the symptoms of localized manifestations of inflammation characterized by acute or chronic swelling, pain, or redness.
9. The method according to claim 7 , wherein said compound is administered by local administration or systemic administration.
10. The method according to claim 7 , wherein said compound is administered by topical administration.